Consensus statement1: Establishing uniform diagnostic criteria is crucial to implementing structured IgAN care across the UAE

Evidence label: Guideline based

Current diagnostic pathways for IgAN across the UAE are non-standardized. Given >90% of IgAN cases are idiopathic [2] and the average age of an IgAN diagnosis is 30 - 40 years [17], a high degree of clinical suspicion is required to achieve a diagnosis. Clinical suspicion for IgAN should arise in the presence of acute kidney injury, hematuria or proteinuria, often coexisting with hypertension, and prompt referral to nephrology should take place upon discovery of any combination of these signs [18]-[20]. While routine screening for IgAN is common in countries with high disease prevalence (e.g., China and Japan) [18], awareness of IgAN is low among general practitioners, internal medicine, and family medicine physicians in the UAE. As such, when evaluating patients for chronic kidney disease (CKD) the inclusion of a work-up for glomerulonephritis, including IgAN, may be warranted given that IgAN remains the most common glomerular disorder identified through biopsy in the UAE [16].

Table 1. Delphi voting results on final consensus statements.

IgAN, immunoglobulin A nephropathy; UAE, United Arab Emirates.

Other than estimated glomerular filtration rate (eGFR) and proteinuria, no validated prognostic serum or urine biomarkers for IgAN exist [17], meaning greater education and awareness is needed among PCPs. In addition, the incorporation of urine analysis into routine checkups is warranted, as urine analyses are not often conducted unless the patient reports issues like urinary problems or pain. We highly recommend undertaking microscopic urine examination upon a positive hematuria result (strongly favored over dipstick tests or machine cytometry), as this plays a crucial role in the early detection of glomerular diseases including IgAN. Once patients have been referred to nephrology in the UAE, some nephrologists advocate proceeding immediately to biopsy in patients with unexplained hematuria, while others only proceed based on detection of proteinuria of >1 g/day. However, as proteinuria is an internationally recognized negative prognostic factor for IgAN [17], we advocate that nephrologists in the UAE adopt a more proactive and timely approach regarding when to proceed to biopsy. We recommend a kidney biopsy should be considered (unless contraindicated) in all adults with proteinuria ≥ 0.5 g/day (or equivalent) in whom IgAN is a possible diagnosis, in line with the latest KDIGO 2025 international guidelines [17].

Red flags for diagnosis include recurrent gross hematuria, particularly during, or shortly after, upper respiratory infections, persistent microscopic hematuria, unexplained proteinuria ≥ 0.3 g/day, early-onset hypertension, and otherwise unexplained reductions in kidney function. Synpharyngitic hematuria and a family history of IgAN or IgA vasculitis provide additional clues (Table 2). The presence of these red flags should trigger prompt referral to nephrology and consideration of kidney biopsy. If red flags are present in a patient, additional consideration should be given to ethnicity, particularly given the increased risk of IgAN in patients of South and Southeast Asian ethnicity who comprise a high number of expatriates to the UAE.

Table 2. Red flags for IgAN diagnosis.

IgA, immunoglobulin A; IgAN, IgA nephropathy.

Consensusstatement 2: KidneybiopsyisanessentialcomponentofIgANdiagnosis,andwerecommendenhancingitsaccessacrosstheUAE

Evidencelabel: Guidelinebased

Obtaining a kidney biopsy is an essential requirement for an IgAN diagnosis. Early biopsy is crucial to ensure timely treatment initiation and prevention or limitation of potential further kidney damage. In line with KDIGO 2025 Guidelines, we recommend a kidney biopsy should be considered (unless contraindicated) in all adults with proteinuria ≥ 0.5 g/day (or equivalent) in whom IgAN is a possible diagnosis [17]. In cases where there is a clinical suspicion for IgAN, for example, when patients co-present with hematuria and reduced kidney function, we recommend the threshold for performing biopsy should be lowered to proteinuria < 0.5 g/day. The diagnosis of IgAN is made by demonstrating the presence of dominant or codominant IgA deposits in the mesangium or capillary loops (accompanied by cell proliferation and expansion) [18]. Next, secondary causes must be excluded before the diagnosis of primary IgAN can be confirmed. These include IgA vasculitis, IgAN secondary to viral infections (e.g., HIV or hepatitis), IgA-dominant post-infectious glomerulonephritis, inflammatory bowel disease, autoimmune disease, and liver cirrhosis [17][18]. A summary of our recommendations for standardized IgAN diagnostic criteria to be adopted throughout the UAE are summarized in Figure 1.

IgA, immunoglobulin A; IgAN, IgA nephropathy; UAE, United Arab Emirates.

Figure 1. Recommendations for IgAN diagnosis in the UAE.

Given the central role of kidney biopsy in achieving an IgAN diagnosis, this needs to be more firmly integrated into clinical practice across the UAE to ensure disparities in access and reimbursement are not an obstacle to diagnosis. A single biopsy is usually sufficient to achieve diagnosis if a thorough risk assessment is carried out, for example, the quality of the biopsy should be rapidly confirmed by assessing the number of glomeruli. An exception is cases of suspected sampling error (e.g., <8 glomeruli) or discordance between clinical presentation and biopsy findings, where repeat biopsy may be considered. Once a diagnosis has been made, patients should ideally be enrolled in a registry, and EMAN-T has begun work on establishing a kidney biopsy registry with external stakeholders. A patient registry is an organized system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure, and that serves one or more predetermined scientific, clinical, or policy purposes [21]. Benefits of a national registry include defining incidence and prevalence, guiding strategic direction, operational standards, and stakeholder collaboration. A registry will provide a more accurate picture of IgAN epidemiology within the UAE’s multiethnic population. It will also enable long-term tracking of kidney outcomes and disease progression and facilitate benchmarking and comparison of clinical performance across UAE centers. The registry can inform clinical pathways and support the development of standardized national protocols, it has the potential to accelerate early adoption and evaluation of emerging therapies through real-world evidence, and support health technology assessments and reimbursement decisions for new treatments. Registries can generate local evidence to address gaps not covered by international cohorts, which is of importance when considering the UAE’s unique ethnic distribution and biopsy practices.

However, there are challenges when establishing a national registry, including necessity of strict compliance with UAE data privacy laws, requirements for robust governance frameworks, secure data management processes, and clear patient consent procedures. There are logistical complexities of standardizing data fields, definitions, and formats across various hospital systems and variability in electronic medical record platforms and documentation practices.

There are some specific challenges and opportunities to improve biopsy access throughout the UAE. These include a lack of recognition that biopsy is a lifesaving procedure in patients with rapid progressive glomerulonephritis or unexplained rapid decline in eGFR. There should be increased clarity in healthcare institutions as to whether interventional radiology or nephrology departments are responsible for biopsy. The biopsy instrument and needle size should be standardized, as well as standardized training provided for the designated department. Identification of Centers of Excellence for biopsy should be considered. These Centers would be regularly audited, including maintenance of logbook for operators, formal training, certification and recertification for operators.

Consensusstatement 3: Standardriskstratificationframeworksshouldbewidelyadoptedtoinformprognosisandhelpcreateapersonalizedclinicalmanagementplan

Evidencelabel: Guidelinebased

At the time of diagnosis, over 50% of patients already have CKD stage 3 - 5 [20], indicating a substantial loss of functional nephrons. This stark observation underlines the need for early action to prevent or limit further kidney decline. As such, early quantification of risk of progression is needed to inform discussions with patients for shared decision-making on the initiation of appropriate therapy as soon as possible. The International IgAN Prediction Tool is the primary method that is currently used in a prognostic manner for risk prediction in patients with IgAN [17]. The tool was designed to predict the risk of 50% decline in eGFR or ESKD following biopsy by integrating clinical and histological factors, including eGFR, blood pressure, proteinuria, age, ethnicity, medication use (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and immunosuppressants) and MESTC scores (based on the kidney biopsy and incorporating mesangial hypercellularity [M], endocapillary hypercellularity [E], segmental sclerosis [S], tubular atrophy/interstitial fibrosis [T], and crescents [C]) [17][18].

It is important to note that ethnicity has the potential to impact risk stratification due to differences in MESTC scores. For example, Chinese and Japanese ethnicities yield a greater 5-year ESKD progression risk than Caucasian ethnicity [17][18]. The International IgAN Prediction Tool has not been externally validated in the UAE’s multi-ethnic population and local validation is urgently needed. The importance of ethnicity is well illustrated when comparing the rate of eGFR decline in the control arms of the phase 3 STOP-IgAN [22][23] and TESTING [24] trials, which included predominantly White and Asian patients, respectively, and were 1.6 mL/min/1.73m² per year for White patients compared with 4.97 mL/min/1.73m² per year in Asian patients.

There are some drawbacks to the International IgAN Prediction Tool, including the exclusion of more modern therapies in its stratification score [18], as well as its limitation of being able to fully capture longer-term risks [25]. As such, there is scope for discovering alternative risk stratification tools that go beyond current markers (proteinuria and eGFR), which are later indicators of disease, and that can be adjusted to incorporate clinical changes over time [25]. Implementation and validation of non-invasive methods to visualize kidney inflammation in IgAN is also an important future goal, and there have been some advances in the use of molecular imaging techniques including positron electron tomography- and magnetic resonance imaging-based methods in this regard [26][27].

A future risk stratification tool should be optimized for use in the UAE by integrating longitudinal variables such as time-averaged proteinuria, and eGFR slope, and adding validated noninvasive biomarkers, when available. Additional ethnicity-specific predictors could be considered to be a factor in the tool. In future, a local validation study is recommended to ensure the risk model accurately reflects the variable access to biopsy and the multiethnic population in the UAE. Ideally risk stratification would have the potential to contribute to a personalized treatment plan for patients.

Consensusstatement 4: IgANmanagementandtreatmentgoalsshouldbeclearlydefinedandstandardizedacrosstheUAE, includingadefinedtreatmentalgorithmwithtreatmentescalationstrategies

Evidencelabel: Guidelinebased

The ultimate treatment goal for IgAN is to prevent progression to ESKD. Specifically, the rate of kidney function decline should be reduced to <1 mL/min per year for rest of patient’s life [17][18]. Currently, the only biomarker to guide treatment decisions is proteinuria, which tracks well with kidney outcomes, and should be maintained at a minimum of <0.5 g/day (ideally < 0.3 g/day). Achievement of this may require multiple pharmacological and non-pharmacological strategies, particularly in patients with extensive kidney scarring [17][18]. Extent of microhematuria is associated with IgAN progression, and is emerging as a potential future therapeutic goal in IgAN management [25]. Ideally, in future, treatment should be personalized where possible, matching treatment options to specific pathophysiological profiles, whereby clinical context encompassing all available data should be utilized. Key factors affecting disease risk, and therefore treatment decisions, include ethnicity and age at presentation, as well as current rate of disease progression.

As a starting point for standardizing IgAN management across the UAE, and in line with KDIGO international guidelines [17], lifestyle modification is recommended in all patients including the achievement of a healthy weight, cessation of smoking, and adaptation of a low sodium diet. From this point, clinical management of IgAN can be broadly split into two main management streams: 1) prevention or minimization of further IgA immune complex-mediated glomerular injury, with the treatment paradigm aimed at slowing disease, inflammation and fibrosis and 2) universal supportive care to provide control of existing CKD (managing the generic response to nephron loss, which is present in newly diagnosed cases at ~50% [20]) (Figure 2).

*When approved for use in the UAE. APRIL, a proliferation-inducing ligand; BAFF, B-cell activating factor; CKD, chronic kidney disease; DEARA, dual endothelin angiotensin receptor antagonists; ERA, endothelin receptor antagonist; GLP-1, glucagon-like peptide-1 IgA, immunoglobulin A; IgAN, IgA nephropathy; MRA, mineralocorticoid receptor antagonist; RASi, renin-angiotensin system inhibitor; SGLT2i, sodium-glucose cotransporter 2 inhibitor; T2DM, type 2 diabetes mellitus; TR, targeted release.

Figure 2. Proposed IgAN treatment algorithm for the UAE.

3.2.1. Preventing or Minimizing Further IgA Immune Complex-Mediated Glomerular Injury

Targeting immunological activity is the most important treatment goal in IgAN management and has the ability to target multiple pathological mechanisms simultaneously to combat disease heterogeneity and achieve effective disease control (Management stream 1; Figure 2). The “four-hit hypothesis” of IgAN pathogenesis provides a useful framework with which to consider immunological treatment interventions and is pertinent for higher-risk or persistent-proteinuria groups. Hit 1 involves increased production of pathogenic Gd-IgA1, followed by Hit 2, which is the production of auto-antibodies against Gd-IgA1 [28]. The third and fourth hits involve, respectively, the generation of and subsequent deposition of circulating immune complexes in the glomerular mesangium, leading to inflammation and fibrosis [28]. Overall, therapies targeting any stage of this four-Hit immunological response are aimed at halting glomerular inflammation, reducing the production of Gd-IgA1, and stopping pro-fibrotic signals in the kidney [28]. While most of these stages are well covered by new and emerging treatments, interventions to directly stop pro-fibrotic signals are lagging behind on the treatment horizon [28].

The STOP-IgAN [22] and TESTING [24] trials provided the first robust randomized clinical trial evidence that on-treatment systemic glucocorticoids were effective at mitigating glomerular inflammation in IgAN. However, long-term use of corticosteroids is controversial due to short- and long-term toxicity, and current KDIGO IgAN treatment guidelines have strict recommendations for their use, with targeted release (TR)-budesonide now recommended ahead of methyl prednisone in patients at risk of progressive loss of kidney function [17]. TR-budesonide is designed to target the gut-associated lymphoid tissue of the terminal ileum to reduce the production of pathogenic Gd-IgA1 (“Hit 1”), and was found to lower urine protein-to-creatinine ratio and limit eGFR loss compared with placebo after 9 months of treatment in the phase 3 NefigArd trial [29][30].

Strategies to target the production of auto-antibodies against IgA1 (“Hit 2”) include B-cell depleting and modification therapies [18][28][31][32]. B-cell depletion therapies utilizing anti-CD20 agents such as rituximab have so far shown limited efficacy [28], while other strategies including CD38 depletion are currently being tested, as are B-cell modification strategies such as inhibition of B-cell activating factor (BAFF) and cytokine A proliferation-inducing ligand (APRIL) (discussed in later section) [18][28][31][32]. Strategies to target the inflammatory pathways in IgAN (driven by Hits 3 and 4) are another major focus of IgAN treatment, with inhibition of complement activation seen by some physicians as an efficacious and safer alternative to systemic corticosteroids in controlling kidney inflammation in IgAN [28]. A summary of our recommended treatment algorithm for standardizing the clinical management of patients with IgAN across the UAE is provided in Figure 2.

3.2.2. Control of Existing CKD

The initial treatment response to nephron loss is aimed at reducing hyperfiltration, proteinuria, and controlling blood pressure with supportive care. Here, in Management stream 2 (Figure 2), maximally titrated renin-angiotensin system (RAS) inhibitors, endothelin receptor antagonists (ERAs), dual endothelin angiotensin receptor antagonists (DEARAs), and sodium-glucose cotransporter 2 (SGLT2) inhibitors—including dual inhibitors are used [17][18]. The PROTECT trial showed that 400 mg of the DEARA sparsentan taken once daily reduced proteinuria and preserved kidney function compared with maximally titrated irbesartan in patients with IgAN [33]. Based on this, sparsentan is recommended by the KDIGO 2025 guidelines [17] in patients with IgAN who are at risk of progressive loss of kidney function. Likewise, KDIGO 2025 guidelines recommend the use of SGLT2 inhibitors based on pre-specified analyses of trials of DAPA-CKD (dapagliflozin) [34] and EMPA-KIDNEY (empagliflozin) [35] studies, which were conducted in a broad range of patients with CKD, including those with IgAN. The pre-specified interim analysis of the ALIGN trial showed that 0.75 mg of the ERA atrasentan per day resulted in significantly and clinically reduced proteinuria versus placebo in patients with biopsy-proven IgAN [36], and its recent approval in the UAE (preceded by the approval in the US by the U.S. Food and Drug Administration), allows its incorporation into local treatment algorithms. Additional molecules under investigation for controlling existing CKD in IgAN include the ERA SC0062, and the mineralocorticoid receptor antagonist finerenone, which is currently used in patients with CKD associated with type 2 diabetes [31].

We propose an initial standardized approach across the UAE to control existing CKD in IgAN by using maximally tolerated RAS inhibitors with or without an ERA or DEARA, and consideration of adding an SGLT2 inhibitor (Figure 2). It is important to note, however, that therapy restricted solely to managing CKD alone should only be considered as a short-term option for low-risk patients in a “wait and watch” approach, because patients restricted to these therapies do not tend to do well longer term, and it is anticipated that these agents may need to be used in conjunction with immune-targeting agents.

Consensusstatement 5: Treatmentalgorithmsshouldbereviewedandupdatedannuallytofacilitatetheincorporationofemergingtherapiesintocarepathways

Evidencelabel: Trialsupported

The number of treatment options for IgAN was limited until relatively recently. There are now a range of treatments across different classes that are recently FDA approved (or expected soon) or undergoing evaluation in clinical trials, with the potential for a dramatic expansion in the treatment landscape in the coming years. As such, it is important that treatment algorithms in the UAE are reviewed every year to ensure that the latest available treatments are incorporated into the algorithm. This will ensure treatments can be personalized wherever possible to suit individual patient profiles.

One area that is undergoing substantial clinical evaluation is the complement pathway. This plays a key role in IgA pathogenesis, driving both glomerular inflammation and mesangial injury, and deposition of C3 is a hallmark of IgAN [18][28][31][32]. Iptacopan specifically inhibits the alternative complement pathway by targeting factor B, and an oral dose of 200 mg twice daily was shown to reduce proteinuria in patients with biopsy-proven IgAN in the APPLAUSE-IgAN trial [37], resulting in its approval for use in the UAE. Several other complement inhibitors are also undergoing evaluation in Phase 2 and Phase 3 trials, including antisense inhibitors of complement B (sefaxersen; RO7434656) and C5 (cemdisiran), inhibitors of complement D (vemircopan), complement C3 (pegce tacoplan), complement C5 (ravulizumab) and complement C5a (avacopan) [18][28][31][32]. Complement inhibitors serve as a useful alternative to corticosteroids, particularly in patients resistant to corticosteroids or in whom a steroid-sparing regimen is required, and will broaden the treatment armamentarium to facilitate a more personalized approach to IgAN treatment [18].

B-cell modification therapies are another class of treatments that are undergoing extensive evaluation in patients with IgaN [18][28][31][32]. The APRIL and BAFF cytokines stimulate B-cell activation, maturation and proliferation, thus ultimately promoting the secretion of immunoglobulins including Gd-IgA1. Sibeprenlimab is an APRIL inhibitor that has recently been evaluated in the Phase 3 VISIONARY trial [38]. That study showed that 400 mg subcutaneous sibeprenlimab every 4 weeks resulted in a significant reduction in 24-hour urinary protein-to-creatinine ratio versus placebo after 9 months of treatment [38], and resulted in its approval by the FDA for the treatment of primary IgAN. A second B-cell modification therapy, the APRIL/BAFF dual inhibitor atacicept, has recently received FDA Breakthrough Therapy Designation for the treatment of IgAN (as of January 2026) based on the results of the ORIGIN 3 trial [39]. That trial showed that a once-weekly subcutaneous injection of atacicept was superior to placebo in reducing proteinuria after the 36-week interim analysis [39].

Additional B-cell modification therapies under evaluation in Phase 2 and Phase 3 trials include the APRIL inhibitor zigakibart and the APRIL/BAFF dual inhibitors telitacicept and povetacicept, with Phase 3 data suggesting promising reductions in Gd-IgA1, proteinuria and slowing of kidney function loss in patients with IgAN [18][28][31][32]. Other B-cell modifying therapies include CD38-depleting monoclonal antibodies (felzartamab, mezagitamab), as CD38 is thought to be closely involved in the formation of Gd-IgA1, and the proteasome inhibitor bortezomib, which results in plasma cell depletion [18][28][31][32]. Identification of which patients are most likely to respond to B-cell modification therapies will be key to incorporation of these agents into treatment algorithms upon first approval.

When considering how to personalize the treatment algorithm for IgAN, supportive care with RASi, SGLT2 inhibitor, and lifestyle modifications should be recommended for all patients regardless of risk category (Figure 2). TR-budesonide should be used in patients with persistent proteinuria (≥0.5 - 1 g/day) despite optimized supportive care and evidence of active mucosal-driven disease and can be useful when systemic steroid sparing is desired. Systemic glucocorticoids can also be used in high-risk patients when TR-budesonide or targeted therapy are unavailable or contraindicated. Mycophenolate mofetil is potentially useful as a corticosteroid-free immunosuppressant, particularly in patients of Chinese origin [17]. A complement inhibitor may be used in patients with high-grade proteinuria, rapid EGFR decline, or biopsy evidence of complement activation or patients who are steroid-resistant or steroid-intolerant.

An overview of ongoing molecules being evaluated in IgAN Phase 2 and 3 clinical trials is summarized in Table 3. The potential for new available treatments underpins our recommendation for an annual review of the treatment algorithm; however, it is acknowledged that this may be logistically challenging. As such, we then advocate a review of the treatment algorithm every two years at a minimum.

The proposed treatment algorithm is endorsed by EMAN-T and accordingly should be incorporated into care pathways in UAE. This will involve endorsement and adoption by the ministries of health and major private healthcare providers. The algorithm should be integrated into electronic medical records and supported by clinical decision prompts to standardize practice across centers. If feasible, an early engagement with the pharmaceuticals and therapeutics committee will streamline formal approval and reimbursement of therapy. To encourage adoption of the national treatment algorithm, CME-accredited education should be provided to nephrologists, pharmacists and PCPs to ensure correct patient selection and monitoring. The treatment algorithm should be piloted through designated Centers of Excellence to refine implementation and collect national data on the therapy. Investment in such centers may also facilitate enrollment in clinical trials, enabling new treatments to reach patients in a timely manner. It is important to ensure equitable access to the treatment algorithm and avoid unnecessary delays.

It is anticipated that multiple new treatments in the IgAN landscape have the potential to shift care from supportive and systemic steroid treatment to mechanism-based target therapy which will improve precision and may lead to a better outcome. There will be an increased ability to reduce proteinuria, potentially slow eGFR decline, and delay ESKD in more patients, with the additional potential to reduce long-term dialysis. However, new therapies will introduce greater complexity in clinical decision-making, requiring patient stratification and a standardized treatment algorithm. Investing in developing specialized centers for the care of patients with IgAN, and other glomerular disorders, that enroll patients to local and international clinical trials will be an important step in improving patient access to new therapies. Once approved, new treatments can incur health economic considerations and may have an impact on hospital budgets; studies should be conducted to analyze this impact and recognize the benefits of increased patient health to national healthcare capacity. Lastly, as with all new treatments, they should be monitored to evaluate efficacy, safety and cost-effectiveness as they are introduced into clinical use.

Table 3. Ongoing IgAN clinical trials that may impact future treatment algorithms in the UAE.

APRIL, a proliferation-inducing ligand; BAFF, B-cell activating factor; ERA, endothelin receptor antagonist; IgAN, immunoglobulin A nephropathy; MRA, mineralocorticoid receptor antagonist; Ph, phase; UAE, United Arab Emirates.

Consensusstatement 6: OngoingeducationonbestpracticeandadvancesinIgANmanagementshouldbeamajorgoal,duetothepotentialtoimprovecarepathwaysandensureanalignedapproachamongallrelevantstakeholdersintheUAE

Evidencelabel: Expertopinion

Awareness of IgAN pathophysiology is generally low among PCPs and nephrologists in the UAE. We have outlined key areas from diagnosis through ongoing management that we believe are important focus points for targeted educational activities to achieve maximum effect with regard to optimizing IgAN care pathways.

Achieving an initial diagnosis is often the first hurdle in the IgAN pathway, with many nephrologists unaware that the threshold for proceeding to biopsy is lowered for suspected IgAN. As such, education is needed on the importance of early biopsy and timely treatment so that these can be more firmly integrated into clinical practice. Similarly, a greater awareness of the most at-risk profiles is needed, including recognizing the increased risk among South Asian expatriate populations compared with UAE nationals. As PCPs are often first to encounter patients with IgAN, they play a large role in early recognition and diagnosis of the disease and accordingly should be targeted in educational programs. The key role of PCPs is even more relevant considering that there are only around 100 nephrologists in the UAE, which is insufficient to diagnose a disease accounting for upwards of 20% of all glomerular nephritis cases [16]. Integral to this, widespread education on the importance of routine urine analysis needs to be more firmly established in primary care, and future implementation of mass screening programs would be beneficial given high prevalence of IgAN.

At the prognosis stage, education is needed to overcome the common misconception among nephrologists that IgAN is not a severe disease, and the risks of progression to ESKD and associated mortality risks need to be more firmly appreciated. In particular, the importance of proteinuria thresholds should be integrated into daily clinical practice, specifically involving greater utilization of proteinuria as a prognostic marker and a shift from the old mindset that levels < 1 g/day indicate a mild disease. In addition to increased awareness of the importance of such prognostic tools, a greater appreciation of the heterogenous nature of disease should be encouraged. IgAN must be recognized among nephrologists as a broad-spectrum disorder, and greater clarity on how to classify and manage diverse patient profiles would be beneficial. Importantly, a greater focus should be placed on early treatment to prevent rapid progression, with a clear understanding of personalized medicine approaches to IgAN with regard to targeting specific pathophysiological profiles. Historically, the lack of biomarkers has led to an overreliance on repeat kidney biopsy to guide treatment, but this approach is not sustainable and additional measures of disease are needed.

To achieve some of these educational goals, we advocate for the development of a practical toolkit, or pocket guide, to aid nephrologists from diagnosis through prognosis and treatment. To facilitate a standardized care pathway across the UAE, a greater establishment of networks is needed between care centers, as well as regular meetings to discuss IgAN management and to share case studies. Current virtual meeting series organized by SEHA Kidney Care and physical and virtual meetings organized by EMAN-T (including the annual glomerulonephritis conference) should be further advertised and could be opened to the wider nephrology network to encourage broader participation, and this could be underpinned by greater collaboration between societies and hospitals.

At the patient level, societies are an excellent way to provide patient educational materials as well as to increase patient voice, for example leaflets in multiple languages to highlight “Understanding IgAN”. These can also have a major impact on policymakers, which can increase awareness of disease for reimbursement reasons. Often, new treatments are expensive, and insurance companies may be reluctant to approve the medication for reimbursement purposes. Studies highlighting cost-effectiveness are often needed, and particularly when placed in the context of future potential dialysis costs, would generally convince payers on the benefits of shorter-term high-cost medications if dialysis could be delayed by 10 years. However, this becomes less justifiable with expatriate patients, who may not remain in the UAE indefinitely. Local guidelines and endorsements from national bodies (e.g., DHA, MoH, Abu Dhabi regulators) would be important to validate the importance of reimbursing treatment costs among policymakers, making it difficult for insurers to deny coverage, and the EMAN-T Society will be critical in this process.